Skip to content

Influence of abnormal autoantibody on adverse pregnancy outcome and infertility

Influence of abnormal autoantibody on adverse pregnancy outcome and infertility - autoantibody and adverse pregnancy outcome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072652
Enrollment
Unknown
Registered
2023-06-20
Start date
2023-06-06
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnancy and infertility

Interventions

ANA positive:None
ANA negative:None

Sponsors

Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1)Women who seek medical treatment from the Rheumatology and Immunology Department, Perinatal Medicine Department or inpatients of Tongji Hospital and are under the age of 45 years old. (2) All patients voluntarily participated in this study and received our regular follow-up and signed relevant informed consent forms.

Exclusion criteria

Exclusion criteria: (1) Chromosome abnormalities in either spouse; (2) The structure of this pregnancy suggests fetal chromosomal abnormalities; (3) Abnormal anatomical structure of Female reproductive system (including unilateral/Bicornuate uterus, mediastinal Uterine malformation malformation, etc.); (4) The woman has gynecological and obstetric diseases with adverse pregnancy outcomes caused by untreated uterine cavity adhesion, Endometrial polyp, adenomyosis, Endometriosis, uterine tumors, etc; (5)Patients who do not agree or are unable to complete follow-up.

Design outcomes

Primary

MeasureTime frame
pregnancy outcome;immune activation;

Secondary

MeasureTime frame
anti-dsDNA antibodies;

Countries

China

Contacts

Public ContactJixin Zhong

Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

jxzhong@tjh.tjmu.edu.cn+86 181 5441 2011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026